Glaukos announces several positive clinical updates for its iDose platform

(Image Credit: AdobeStock/NanSan)

Glaukos has announced several positive clinical updates for its iDose sustained-release procedural pharmaceutical platform.

The iDose TR (travoprost intracameral implant) is a long duration prostaglandin analog approved for a single administration for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). It is implanted through the trabecular meshwork and back wall of Schlemm's canal, directly into scleral tissue.¹

In a new 36-month follow-up analysis of the company’s 2 Phase 3 pivotal clinical trials, iDose TR 75 mcg demonstrated sustained substantial IOP reductions. Furthermore, approximately 70% of iDose TR patients remained well-controlled on the same or fewer IOP-lowering topical medications at 36 months after a single administration, versus 58% of timolol control subjects.¹

Additionally, the company announced that it has commenced a Phase 2b/3 clinical program for iDose TREX. According to the company, iDose TREX is nearly identical in design to the iDose TR, but features nearly twice the drug capacity.¹

Glaukos also released a new 6-month follow-up analysis of a Phase 4 single-arm clinical study that evaluated 60 OAG patients that showed iDose TR implanted in combination with cataract surgery achieved a mean IOP reduction of 11.3 mmHg, or 44%, at 6 months compared to baseline.¹

Thomas Burns, Glaukos chairman and CEO, commented on the announcements in a press release from the company.

“We are pleased to share these positive clinical updates on our iDose procedural pharmaceutical platform, helping to further advance our goal to position iDose as a transformative novel platform technology able to fundamentally improve the treatment paradigm for patients with glaucoma or ocular hypertension,” said Burns. “We continue to believe there is an important unmet clinical need and strong appetite within the ophthalmic community for safe, effective and sustained procedural pharmaceutical alternatives to traditional topical medications.”

The iDose platform is designed to address ubiquitous patient non-adherence and chronic side effects associated with topical medications by providing 24/7, long-duration, robust efficacy with minimal side effects.¹

References:

1. Glaukos Announces Positive Clinical Updates for its iDose^® Sustained-Release Procedural Pharmaceutical Platform. Press Release. Published January 14, 2025. Accessed January 20, 2025. https://www.businesswire.com/news/home/20250114301306/en/Glaukos-Announces-Positive-Clinical-Updates-for-its-iDose%C2%AE-Sustained-Release-Procedural-Pharmaceutical-Platform